Studies have found that ocular toxicity, including central serous retinopathy, is the class effect of known mitogen-activated protein kinase pathway inhibitors (Loriot et al., 2019), potentially related to erdafitinib’s inhibition of FGFR-related downstream pathways. Here, WNK2 is linked to central serous retinopathy.